Friday, July 15, 2005

Cancer drug enters phase-I/II trials

DRUG major brand Nicholas Piramal India Ltd has claimed that its prospective anti-cancer drug molecule has entered into Phase I and II clinical studies. After obtaining the necessary permissions from the Canadian regulatory authorities, a patient was recently infused intravenously with P276-00 at an Oncology centre in Canada. It is expected that it could take 9-12 months to enrol 30-35 patients to complete the Phase I/II study that will help determine a safe and possible efficacious dose, which will be used for further clinical studies. The prospective cancer drug molecule is the first in a series of compounds from the company's research centre to enter into clinical trials. It is an inhibitor of a key protein that is required by the cells to divide. Based on the initial laboratory data, P276-00 appears suitable as an agent to treat lung, breast and colon cancers.